# KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Source: https://onco.cc/trials/nct07481058/  
OnCo record `nct07481058` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of KC1036, Toripalimab and Cisplatin in oesophageal cancer, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.

## Summary

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer is a phase 2 interventional study registered as NCT07481058 by Beijing Konruns Pharmaceutical Co., Ltd., with 60 participants planned, started 2025-12-12 and due to reach its primary completion in 2027-12. Interventions recorded: KC1036, Toripalimab, Paclitaxel and Cisplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07481058
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of KC1036 Combined With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07481058: https://clinicaltrials.gov/study/NCT07481058

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [KC1036](https://onco.cc/drugs/kc1036/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Beijing Konruns Pharmaceutical](https://onco.cc/companies/beijing-konruns-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07481058.json